Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study-Reference-Cited by-同舟云学术

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study

Published:2023-07 Issue:7 Volume:23 Page:515-526
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Shadman Mazyar,Manzoor Beenish S.,Sail Kavita,Tuncer Hande H.,Allan John N.,Ujjani Chaitra,Emechebe Nnadozie,Kamalakar Rajesh,Coombs Catherine C.,Leslie Lori,Barr Paul M.^ORCID,Brown Jennifer R.,Eyre Toby A.,Rampotas Alexandros^ORCID,Schuh Anna,Lamanna Nicole,Skarbnik Alan,Roeker Lindsey E.,Bannerji Rajat^ORCID,Eichhorst Barbara,Fleury Isabelle,Davids Matthew S.,Alhasani Hasan,Jiang Dingfeng,Hill Brian T.,Schuster Stephen J.,Brander Danielle M.,Pivneva Irina,Burne Rebecca,Guerin Annie^ORCID,Mato Anthony R.

Funder

AbbVie

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference38 articles.

1. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia;Del Poeta;Drugs Today (Barc),2016

2. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice;Sanford;Clin Lymphoma Myeloma Leuk,2015

3. Venetoclax for the treatment of chronic lymphocytic leukemia;Gentile;Expert Opin Investig Drugs,2017

4. Current treatment of refractory/relapsed chronic lymphocytic leukemia: a focus on novel drugs;Smolewski;Acta Haematologica,2021

5. Sequencing of chronic lymphocytic leukemia therapies;Barrientos;Hematology Am Soc Hematol Educ Program,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world comparative effectiveness of venetoclax‐obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia;British Journal of Haematology;2024-07-24

2. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton’s tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting;Journal of Managed Care & Specialty Pharmacy;2024-07-24

3. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24

4. Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era;Pharmaceutics;2023-12-29

5. Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study;Cancers;2023-08-10